会议主要讨论的核心内容 - 公司认为CGM市场仍是一个高增长市场 CGM渗透率在美国Type 1糖尿病患者中达60%-65%、Type 2重症患者中达50%-55%、基础胰岛素患者中达20%-25%,而非重症Type 2糖尿病患者市场还有很大机会 [2][3] - 公司正在采取措施应对竞争对手Abbott在某些细分市场的优势 包括加强销售团队管理、与主要分销商建立更紧密的合作关系 [4][5][6][7] - 公司计划在2025年推出15天使用期的G7产品 已经提交FDA审批 [8][9][10][11] - 公司长期增长目标仍然是15%-20% 尽管短期内受到一些执行问题的影响 [15][16][17] 问答环节重要的提问和回答 - 分析师关注公司在DME分销渠道的市场份额下降 公司表示是由于销售团队调整和渠道中性策略执行不力造成的 正在采取措施加强与DME分销商的合作关系 [20][21][22][23][24][25][26][27] - 分析师关注公司在Medicare Advantage患者群体中的表现 公司表示这主要是由于销售团队在推广渠道中性策略时出现偏差 正在纠正这一问题 [29][30][31][32] - 分析师对Stelo产品的市场反响和定价策略提出询问 公司表示初期反响良好 正在收集用户反馈并优化产品体验 定价策略经过充分市场调研 未来会根据市场情况适当调整 [48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67] - 分析师对公司2025年的财务目标提出质疑 公司表示主要依靠销售团队的提升、Stelo产品的贡献以及国际市场的增长来实现 [68][69][70][71][72][73]

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom as well as certain of DexCom’s top executiv ...

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

SAN FRANCISCO, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges DexCom, Inc. (NASDAQ: DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com                                            844-916-0895 DexCo ...

RADNOR, Pa, Sept. 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024. CONTA ...

The stock has delivered superior returns in the past 19 years.Medical device specialist DexCom (DXCM -0.40%) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps put things in perspective. The healthcare company has generally delivered returns that are well above average. Can DexCom continue doing that long enough to be a millionaire-maker stock for investors who get in today? Let's find out.What DexCom doesDexCom i ...

NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline in the securities class action. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) --  Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) a ...

SAN FRANCISCO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges DexCom, Inc. (NASDAQ: DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com  844-916-0895 DexCom, Inc. (DXCM) Securities Class Action: D ...

RADNOR, Pa., Aug. 30, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the "Class Period") The lead plaintiff deadline is October 21, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered DexCom losses, you may CLIC ...